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Lack of transparency, wrongdoings, and unlawful promotion characterize the
healthcare industry; these are especially prevalent within the pharmaceutical
industry. Consequently, an investigation into the evidence of the corruption and the
ethical infringement is needed. In this paper, I will evaluate the pharmaceutical
industry’s adherence to the three major branches of ethics. The ever-increasing
prices of pharmaceutical products, especially medications used for the combating of
anaphylaxis and cancer, coupled with the compensatory-based medication
promotion and research points to a major crisis in the realm of social justice. These
examples, among many other current issues, lead to difficulties in individuals
receiving the medications they truly need, either because they cannot afford them or
the information is being withheld. Recent price hikes in medications also raise
questions of whether this industry is truly providing for the health needs of all
individuals or if it is merely preying on profit-generating opportunities.
Over recent years, the healthcare
industry has been under fire due to an everincreasing realization of their lack of
transparency, wrongdoings, and unlawful
promotion – these things are especially
evident within the pharmaceutical industry.
The increased realization of corruption in
this industry may have come about because
of the increasing prevalence of highdeductible healthcare plans that allow the
public greater exposure to the true cost of
their medications. The astronomical prices
of pharmaceuticals, especially for
medications used for combating lifethreatening events such as anaphylaxis and
cancer, point to a major ethical dilemma as
they restrict the number of individuals who
can access the medications they need.
Public discontent with the
pharmaceutical industry may also be due to
the increasing prevalence of news stories
that highlight unethical “marketing
agreements” and the promotion of
pharmaceuticals that may not even work for
what they have been prescribed, as well as
the existence of proprietary partnerships
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between prescribing doctors and
pharmaceutical companies. This
combination of occurrences raises questions
as to whether the industry is truly providing
for the healthcare needs of all individuals;
or, perhaps it is merely preying on profitgenerating opportunities. The evident
corruption surrounding pharmaceutical
companies and the outlandish prices charged
for their products warrant an investigation
into the ethical infringements being made by
the industry. The claims of corruption
surrounding the pharmaceutical industry can
be investigated through an evaluation of
case studies and a discussion of ethical
practices of this industry with consideration
to the ethics, or lack thereof, displayed in the
case studies.
Case Studies
EpiPen Price Increase
A major ethical impingement of the
pharmaceutical industry that has been a
topic of great debate in recent months is the
soaring cost of the EpiPen, which has
undergone a 400% price increase since
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being acquired by Mylan in 2007. While this
device was originally developed as a nervegas antidote, it was discovered shortly
thereafter to be exceedingly valuable as a
treatment for life-threatening allergic
reactions.1 The dosage delivery mechanism
found within the EpiPen has also been
patented, making it the only immediate
anaphylactic treatment with the capability to
calculate the exact dose needed to be
injected into the victim.2 This patented
mechanism and the device’s life-saving
value provide grounds which Mylan can use
to further increase the price of the device as
they are able to market this unique, lifepreserving device. However, in the event of
a life-threatening allergic reaction, two
EpiPens are needed if the victim has not
entered medical care within 15 minutes of
the first dose. Due to not being able to
predict the situation in which one will be at
the onset of anaphylaxis, it is imperative that
two EpiPens are always carried to prevent
an event more serious than the onset of
anaphylaxis, doubling the cost of an already
expensive device so widely needed. For
families with one or more anaphylactic
children, an innumerable amount of devices
are needed so that one is always within
reach when the victim is exposed to an
anaphylactic trigger.
With the price for a two-pack of
EpiPens increasing from $57 to $608 in the
decade that it has been owned by Mylan, the
outlandish prices for such a crucial
pharmaceutical are beginning to be felt more
than ever as greater numbers of Americans
transition into low-premium, highdeductible healthcare plans with higher outof-pocket costs for prescription medications.
Many are feeling as though they have no
choice but to devise a way around the
pharmaceutical industry to get the protection
they need by buying pre-filled vials of

epinephrine inject themselves with, while
other pharmaceutical industries, such as
CVS, are attempting to design a product that
does basically the same thing, but with a
two-pack cash price a sixth of the cost of the
Mylan brand.3 This CVS-produced generic
has been coined Adrenaclick and its
convenient debut after the outlandish price
of the Epi-Pen began getting national
attention begs the question of if CVS is
marketing this generic because they see a
widespread need for it or because they saw
the ability to capitalize on the exposure of
Mylan’s ridiculous pricing.
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Orphan Drug Act of 1983
Another recent event that brings
ethical practices into question was the
publishing of an article this February that
outlines how individuals with rare diseases
or in low-income brackets are unable to
obtain the medication required for treatment
due to exceedingly high prices.4 The
inability for those individuals with rare
diseases to obtain the necessary medications
proves excruciatingly difficult, even under
the Orphan Drug Act of 1983. The Orphan
Drug Act was enacted as a way for the
government to provide incentives in the way
of tax breaks to companies who have the
capability to produce a drug needed and
drive research for rare diseases, such as
Huntington’s disease or Amyotrophic
Lateral Sclerosis (ALS), but do not have the
financial capability to completely fund the
costs associated with the research and
development of these drugs. The costs
associated with the research and
development of new pharmaceuticals are
partly due to the Kefauver-Harris
Amendment, which mandates that
companies prove the safety and
effectiveness of pharmaceutical agents
before marketing begins, setting forth
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excruciatingly high standards for which
drugs in research and development must
pass. Despite these high standards, the
number of orphan drugs produced prior to
the Orphan Drug Act was less than 50 and
now the number of available over drugs is
well over 1,000.
While the combination of the Orphan
Drug Act and the Kefauver-Harris
Amendment have increased the availability
of drugs for rare diseases as well as the
safety and effectiveness of these drugs, they
rarely increase the obtainability of the drugs
as the resulting prices of drugs developed
are far beyond the realm of affordability for
many Americans. The government’s
jurisdiction in encouraging or regulating the
production of these Orphan Drugs
unfortunately does not extend into a
capability for regulating the market price of
these pharmaceuticals.5 Since research and
development far outweigh the potential
profit from producing an orphan drug and
the loss is not easily recouped through
government incentives, pharmaceutical
companies often charge more than 100
dollars per pill of an orphan drug. These
prices often even extend into the several
hundred dollars per pill range. This is an
example of the pharmaceutical industry
capitalizing on human illness. Also, when
companies partake in these activities, they
are acting against the Lord and withholding
these medicines from those who need it
most.6
Eli Lilly and Company
A final case study on the topic of
ethical deficiency in the pharmaceutical
industry arises from a major pharmaceutical
company, Eli Lilly, whose headquarters are
in Indianapolis, Indiana. This company
retains good standing in Indiana regardless
of their questionable activity since it is often
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overlooked with a preference for looking
towards the good this company does in their
home state. The Lilly Foundation, a division
of Eli Lilly, strives toward making drastic
improvements in global health during this
century and the Lilly Endowment
Scholarship Program awards almost 150
Indiana students with a full-ride scholarship
to an Indiana state university of their choice
every year. However, in recent years, this
company has been involved in several
corrupt acts, with one of the more major
ones involving charges brought against Eli
Lilly by the US Securities and Exchange
Commission, or SEC.
Charges brought against Eli Lilly by
the SEC arose after the discovery of offshore “marketing agreements” made by
subsidiaries of Eli Lilly and involved the
transfer of large sums of money to off-shore,
third-party accounts to individuals in Russia,
Brazil, China, and Poland. The money
transferred to these accounts was then being
funneled to government officials to secure
millions of dollars from the country’s
pharmaceutical markets.7 During court
proceedings, it was uncovered that Eli Lilly
had known about their subsidiaries’ corrupt
actions and violation of the Foreign Corrupt
Practices Act, or FCPA, yet chose to not
take further action. During the same time
that these charges and the proceedings were
made public, Eli Lilly released a statement
that they would be increasing the number of
scholarships they provide by about 50 per
year. Whether coincidence or a strategic
ploy to take attention off their corruption, it
successfully hid their wrongdoings from
their immediate community.
Discussion of Ethics
A critical evaluation of each of these
three case studies within the framework of
the three major forms of normative ethics
“SEC Charges Eli Lilly and Company with FCPA
Violations,” 2012.
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first warrants a discussion as to what exactly
normative ethics are.8 Normative ethics is
the study of ethical actions and explores the
way in which humankind ought to act. In
simpler terms, normative ethics sets forth a
framework for which actions are right and
which actions are wrong, both with a sense
of morality. The three major branches of
normative ethics are eudaimonism,
deontology, and consequentialism. Each of
these branches deal with the determination
of what is morally right and wrong in
different ways. These three approaches leave
out the relatively recent evolutionary ethics,
but as this field is still developing and pulls
most its points from the other three forms,
its absence will not detract much from the
discussion. The first approach of normative
ethics to be investigated will be
eudaimonism, or virtue ethics, which
focuses largely on social justice. Next,
deontology, or Kantian ethics, which puts
forth the notion of universality in
determining whether an action is good or
bad. Lastly, discussion will be entered on
consequentialism, or utilitarian ethics. This
branch of ethics holds that the determination
of whether an action is morally good or bad
lies in whether it maximizes utility.9
Eudaimonism
The first approach of normative
ethics, eudaimonism, is an approach that
emphasizes social justice. With the taking of
the Hippocratic Oath and the integral nature
of justice within the realm of public health,
the entire health industry should maintain
vision on the goal of helping those who need
it, whether they can afford it or not.10
Considering the three case studies delineated
above, it appears that eudaimonism is not
upheld within the pharmaceutical industry as
social justice is often pushed aside to make
way for capitalizing on human illness.
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However, this form of ethics is not action
guiding, but focuses on the end goal of an
objective state of happiness with its primary
concern on the agent’s own character.11 This
industry continually finds new ways to
capitalize on those who are in desperate
need of medication as well as those who are
incompetent about medications. Through the
constant seeking for areas where
capitalization is possible, pharmaceutical
companies continually disregard the
adherence to this form of ethics.
When CVS produced the
Adrenaclick in response to the need
plaguing the market, it is most likely that
they saw the potential for profit and sprung
to action. However, CVS could have wanted
to truly fill a gap in the market to ensure the
well-being of all those who suffer from lifethreatening allergic reactions. The action
taken by CVS could fit into the realm of
eudaimonism and the end-goal of objective
happiness as it allows for the survival of
many who would be unable to afford this
emergency medication otherwise. However,
in the case of Eli Lilly’s subsidiaries
securing large portions of the
pharmaceutical markets in foreign countries
there is found a major violation of this form
of ethics as the only benefit to arise from
their behavior was the accruing of greater
profits. Without a decrease in the price of
pharmaceutical agents or increased
availability, no progress was made toward
an objective state of happiness as many that
contain the will to live a full life were still
unable to get the medications required to
make their will a possibility. Lastly, in the
case of the Orphan Drug Act, despite the
efforts of the government to encourage the
production of pharmaceutical agents for rare
disease and the inability of the government
to regulate the prices a major detraction
from social justice is felt. If no one can
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afford these medications, the individual in
need is going to be unable to receive the
medications they need and the company is
going to be unable to make a profit, in no
way are they going to add to reaching an
objective state of happiness.
Deontology
The next approach at ethics is
deontology, or Kantian ethics, which
focuses on the only intrinsically good thing
as being a good will. This branch of ethics
also puts forth that for an action to be
permissible, it must be able to be applied to
all people without contradiction as to if it is
the right action.12 While this is difficult to
achieve, there are a few situations that can
occur within the pharmaceutical industry
that can be agreed upon as being the wrong
action. As an example, doctors will
prescribe medication to patients without
certainty of its full effect to fulfill an
agreement with a pharmaceutical or research
company. This action not only goes against
the Biblical command to treat others as one
would want treated, but also impedes upon
this form of ethics as many medical
professionals would not want a
pharmaceutical agent whose complete
effects are not known to be used on them
nor would they want to unknowingly be
used as a subject in a study.13 This approach
to normative ethics also asserts that humans
should not be used as means to an end, such
as profit or an approved drug, because they
are ends in themselves. Considering this, all
three of the case studies discussed above
violate this form of ethics, in some form or
another, as they strive towards capitalizing
human illness.
Consequentialism
The last form of normative ethics to
be discussed is consequentialism, or
12
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utilitarian ethics. This approach to ethics
believes that the best action to take is the
one that maximizes utility, or the sum of all
pleasure that can be derived from an action,
to the greatest extent. Consequentialism also
believes that the consequences of any action
are the only by which one can measure
whether it is morally right or wrong.14
Utilitarianism shifts its focus outward and
takes other’s interests into account when
making the decision between right and
wrong, also, and can often be found being
applied to social welfare economics and the
crisis of global poverty. With
pharmaceutical companies setting outlandish
prices for medications needed by their
customers, they are only thinking of
themselves and recouping their expenditures
or generating a profit, and are therefore in
violation of this branch of ethics. This can
be found to be true of Mylan, in their 400%
price increase, as well as the astronomical
prices of the drugs developed under the
Orphan Drug Act. However, the competition
provided by these high prices does allow
space and motivation for the development of
innovative pharmaceutical agents.
Aside from these case studies, a
major point of concern within the ethical
practices of the pharmaceutical industry is
the ability of many powerful pharmaceutical
firms to influence the research scientists and
the publications on the medications they
have developed. When the safety and
effectiveness research of a pharmaceutical
agent is funded by the producing company,
there are three main ways that corruption
can occur within the research, including the
conflict of norms and the creation of
dependency networks.15 While the negative
influence often occurs as the result of a
monetary incentive from the pharmaceutical
industry to the researchers, it could also
arise from fear of what could happen to the
14
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research firm should they disprove what the
company is claiming the drug does.16 This
inadequacy in disproving those drugs which
do not work, or the continual occurrence of
Type I errors in their data, often leads to the
distribution of misleading information and
medical practitioners prescribing
medications that are not the best fit for their
patients.
Conclusions
All of this is not to say that there
have not been revolutionary advances in the
ethics of the pharmaceutical industry in the
recent years. Whether these have come
about due to the enactment of new
regulations or to provide better for the
general welfare of society, they have
nevertheless occurred. Increased
transparency to companies’ unethical
practices for consumers, as well as the
increasing calls for globalization, has called
consumers to be more involved in the
sourcing of their healthcare all-around,
especially within the pharmaceutical
industry.17 In the past, there have been cases
of agreements between prescribing doctors
and pharmaceutical researchers that have led
to individuals being prescribed a medication
that they are not yet sure works. This has
been mostly eradicated through the
enactment of the Kefauver-Harris
Amendment, which demands extensive
testing to prove the effectiveness and safety
of each pharmaceutical that is released.
Introduced in 1981, the International
Federation of Pharmaceutical Manufacturers
and Associations, or IFPMA, has been
devoted to moving the pharmaceutical
industry to adopt a self-regulatory ethical
compliance model and increase the number
of transparent relationships between
pharmaceutical companies and consumers.18

16
17

Rodwin, 2013.
Shaw & Whitney, 2016.

Dialogue & Nexus | Fall 2016-Spring 2017 |Volume 4

The end goal of the initiatives set forth by
IFPMA is really the ability to provide
effective care for its patients.
While the pharmaceutical industry
has been under fire within the past several
years for partaking in unethical behaviors, a
lack of transparency amid globalization, and
unlawful promotion and production of
medications, it is truly in the process of
minimizing the occurrence of these things.
The unethical behaviors of the
pharmaceutical industry are being combated
through the Orphan Drug Act, despite its
current shortcomings, the Kefauver-Harris
amendment, and the work of the
International Federation of Pharmaceutical
Manufacturers and Associations. Unlawful
promotion and production of
pharmaceuticals is approaching a minimum
as consumers have begun to take it upon
themselves to become more informed as to
the medications they have been prescribed.
This is especially true through the continual
technological advances that make almost
everything accessible at an individual’s
fingertips. The monopoly held by Mylan
with the EpiPen is coming to an end as the
CVS-produced Adrenaclick available for a
sixth of the cost allows anaphylaxis sufferers
on low-premium, high-deductible plans to
obtain a safer method of delivering the
much-needed combatant into their system
quickly without the use of a pre-filled
adrenaline syringe. While there is truth
behind the claims of corruption surrounding
the pharmaceutical industry, efforts are
continually being made to combat this
corruption and the individuals behind the
pharmaceutical industry are no less human
than the rest of mankind are in a continual
battle with sin, often in the forms of power
and greed.
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